ACRO’s Diversity and Inclusion in Clinical Trials Committee was formed in 2020 as a part of ACRO’s ongoing efforts to work towards advancing diversity, equity, and inclusion in the clinical research ecosystem.
ACRO’s Diversity, Equity, and Inclusion Principles Statement, created by members of ACRO’s D&I Committee, is comprised of four principles that are vital to the work of ensuring all trials are diverse, inclusive, and equitable. By focusing on the four principles and associated actions below, the CROs and technology providers of ACRO are working towards a clinical research ecosystem that is representative of the world we live in.
ACRO’s D&I Advocacy team is tasked with leading efforts to engage with policymakers and regulators on topics relating to improving diversity and inclusion in the clinical research ecosystem. The team has been involved on policies including Congressional reauthorization of PDUFA and FDA’s Race and Ethnicity Diversity Action Plans.
ACRO’s D&I Communications team leads ACRO’s outward messaging on our diversity initiatives. The team spearheaded the development of the D&I Principles Statement and plays an active role in ACRO’s social media communications related to diversity and inclusion in clinical trials.
ACRO’s D&I Collaboration team works with BIO, MRCT, and other stakeholders- including industry, patient, and professional groups- to drive advancements in clinical trial diversity and inclusion.
ACRO’s D&I Workforce team is developing strategies for improving diversity and inclusion within the workforce of our member companies to help, in turn, drive diversity and inclusion among trial participants.
